Form 8-K · Current report
Bio-Techne 8-K, filed Aug 12, 2026
- Filed
- CIK
- 0000842023
- Accession no.
- 0001104659-26-094391
Summary
Bio-Techne reported fourth-quarter fiscal 2026 organic revenue growth of 3% and flat full-year revenue, and announced a cash dividend. As previously announced, Bio-Techne agreed to be acquired by Merck KGaA for $73 per share in cash, an approximately $11.3 billion enterprise value, and CEO Kim Kelderman said the company continues to make progress toward completing the transaction.
Key points
- Fourth-quarter fiscal 2026 net sales rose 1% to $321.2 million, with organic revenue up 3%.
- Fourth-quarter GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52, down from $0.53.
- Full-year fiscal 2026 GAAP EPS rose to $1.16 and adjusted EPS to $1.93.
- As previously announced on June 25, 2026, Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, an enterprise value of about $11.3 billion, and Bio-Techne is no longer holding quarterly investor conference calls because of the transaction.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on August 12, 2026, describing the results of operations for the quarter and year ended June 30, 2026, and its financial condition as of June 30, 2026 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.